To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare.

H.R. 905/S. 733, to amend Part B of title XVIII of the Social Security Act. Meetings/education regarding physician and pharmacy reimbursement issues. Implementation of the Affordable Care Act.

Client expense: $600,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)

H.R. 905 and S. 733 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. ASP Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation.

Client expense: $390,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

H.R. 905 and S. 733 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. H.R. 1483, Drug Safety Enhancement Act of 2011, provisions related to pharmaceutical pedigree, wholesale transaction documentation, and electronic tracking. H.R. 3026, Safeguarding America's Pharmaceuticals Act, provisions related to pharmaceutical pedigree anti-counterfeiting. S. 1584, Drug Safety and Accountability Act of 2011, provisions related to pharmaceutical pedigree anti-counterfeiting. Preserving Access to Life-Saving Medications Act (H.R. 2245, S. 296), provisions related to drug shortages.

Client expense: $390,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)

Client expense: $630,728 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), SENATE, White House Office

FY13 Labor HHS Appropriations legislation; issues related to FDA user fee reauthorization; H.R. 942; S. 1577; S. 3187; Pedigree and biologics issues; H.R. 905; ASP issues; H.R. 5651

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

- HR 905/ S 733, "To Amend Part B or Title XVIII of the Social Security Act to exclude customary prompt pay discounts from Manufacturers to Wholesalers from the average sales price for drugs & biologicals under Medicare", regarding all provisions. - HR 1041, "The Fairness in Medicare Bidding Act", regarding all provisions. - Issues related to Medicare reimbursement for Clinical Laboratory Services. - HR 1041, "Fairness in Medicare Bidding Act", regarding all provisions. - Medicare Part D Letter - HR 452, "Medicare Decisions Accountability Act of 2011", regarding all provisions. - S 668, "Health Care Bureaucrats Elimination Act", regarding all provisions. - Issues related to Physician-owned Companies that manufacture or distribute medical devices. - S 1468/ HR 2787, "Medicare Diabetes Self-Management Training Act of 2011", regarding all provisions. - PL 112-96, "Middle Class Tax Relief and Job Creation Act of 2012", provisions regarding Medicare clinical laboratory services. - Issues related to implantable medical devices. - HR 5998, "USPSTF Transparency and Accountability Act of 2012", regarding all provisions.

Client expense: $880,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)

H.R.905 and S.733, legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. H.R. 1483, H.R.3026 and S.1584, pharmaceutical pedigree anti-counterfeiting legislation. H.R.2245 and S.296, legislation pertaining to drug manufacturing shortages.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.905 and S.733, legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. ASP Generally (in the context of deficit reduction).

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislative proposals related to prompt pay discounts for drugs and biologicals under Medicare Part B, including S. 733 and H.R. 905; federal policy regarding proposed changes to Medicare drug reimbursement average sales price (ASP) formula; ASP generally (in the context of Deficit Reduction).

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Implementation of HR 1; Prescription Drug and Modernization Act of 2003; Issues relating to PDUFA, stimulus, issues relating to PDUFA, stimulus, issues relating to comparative effectiveness and CMS coverage of FDA approved therapies; issues related to the PPS rule involving stroke guidelines; Implementation of the the follow-on biologics in P.L. 1111-148 "Patient Protection and Affordable Care Act; FY13 Labor HHS Appropriations legislation; issues related to FDA user fee reauthorization; H.R. 942 S. 1577, S 3187; Pedigree and biologics issues; H.R. 905; ASP issues: H.R.5651; Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis; Medicare prescription Drug and Modernization Act of 2003; Avastin use in breast cancer treatment; general patient reform issues; implementation of the Affordable Care of 2010; proposed cuts to Part B reimbursement; 340 B reimbursement policy; Medicare/Medicaid Reimbursement

Client expense: $1,129,400 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 905 & S. 733 Average Sales Price P.L. 111-148 - Patient Protection and Affordable Health Care Act Implementation

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Patient Access to Drugs in Shortage Act (HR 6611) Cancer Drug Shortages Medicare SGR-based MD Reimbursement HR 905 Medicare Prompt Pay Legislation

Client expense: $158,250 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

**see addendum page Reimbursement for prescription drugs - Average Sales Price (H.R. 905/S. 733) PL 111-148 - The Patient Protection and Affordable Care Act, PL 111-152 - The Reconciliation Act of 2010, implementation, AMP, 340B, NADAC

Client expense: Not reported · Firm income: $60,000

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

ASP reimbursement policy; Pharmaceutical distribution reimbursement; H.R.905/S.733-- Excluding customary prompt pay discounts from ASP; drug shortages

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 905 / S 733 - To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicasl under Medicare. General issues related to the sustainable growth rate. General issues related to clinical data registries participation in quality reporting for Medicare.

Client expense: $41,666 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Average Sales Price (H.R. 905/S. 733); PPACA Implementation (PL 111-148); Centers for Medicare and Medicaid Services (AMP and NADAC)

Client expense: $228,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 1409: All provisions of the Quality Health Care Coalition Act of 2011; H.R. 891/S. 274: All provisions of the Medication Therapy Management Benefits Act of 2011; H.R. 905 /S. 733:All provisions of the legislation to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare; H.R. 979 - All provisions of the FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act H.R. 605 / S. 312 -All provisions of the Patients Freedom to Choose Act S. 27 - All provisions of the Preserve Access to Affordable Generics Act S. 31 - All provisions of the Prescription Drug and Health Improvement Act of 2011 S. 44 -All provisions of the Medicare Prescription Drug Price Negotiation Act of 2011 H.R. 999 / S. 560 - All provisions of the Medicare Prescription Drug Savings and Choice Act of 2011 H.R. 1839 - All provisions of the Community Pharmacy Fairness Act of 2011; H.R. 1946 - All provisions of the Preserving or Hometown Independent Pharmacies Act of 2011; H.R. 1971 / S. 1058 - All provisions of the Pharmacy Competition and Consumer Choice Act of 2011 Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, value-based insurance design, e-prescribing, PBM disclosure requirements, and medical loss ratio) Regulatory and proposed legislative changes to Medicare part D including EGWP waivers, MTM expansion, long term care short-term fills, recovery audit contractors Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs FDA issues related to the Prescription Drug User Fee Act (PDUFA) (generic user fees, pedigree, REMs); implementation of approval pathway for generic biologic drugs 340b program H.R. 2672 the Preserving Access to Orphan Drugs Act H.R. 2182 the Generating Antibiotic Incentives Now Act H.R. 3026 the Safeguarding Americas Pharmaceuticals Act H.R. 2746 the Cancer Drug Coverage Parity Act H.R.4215 - All provisions of the Medicare Pharmacy Transparency and Fair Auditing Act

Client expense: $518,430 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Labor, Dept of (DOL), SENATE

H.R. 891/S. 274: All provisions of the Medication Therapy Management Benefits Act of 2011; H.R. 905 /S. 733: All provisions of the legislation to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare; S. 31: All provisions of the Prescription Drug and Health Improvement Act of 2011; S. 44: All provisions of the Medicare Prescription Drug Price Negotiation Act of 2011 H.R. 999 / S. 560 - All provisions of the Medicare Prescription Drug Savings and Choice Act of 2011 Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, value-based insurance design, e-prescribing, PBM disclosure requirements, and medical loss ratio) Regulatory and proposed legislative changes to Medicare part D including EGWP waivers, MTM expansion, long term care short-term fills, recovery audit contractors Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs Regulatory Implementation of the HITECH Act FDA issues related to the Prescription Drug User Fee Act (PDUFA) (generic user fees, pedigree, REMs); implementation of approval pathway for generic biologic drugs 340b program H. R. 1290/S. 1206 - All provisions of The Medicare Prescription Savings Act Health care issues before the Joint Select Committee on Deficit Reduction H.R. 3613 the Part D Beneficiary Appeals Fairness Act S. 1356 / H.R. 3343 the Affordable Medicines Utilization Act H.R.4215 - All provisions of the Medicare Pharmacy Transparency and Fair Auditing Act

Client expense: $518,430 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Labor, Dept of (DOL), SENATE

H.R. 5: All provisions of the Help Efficient, Accessible, Low-cost, Timely Healthcare (HEALTH) Act of 2011; H.R. 1409: All provisions of the Quality Health Care Coalition Act of 2011; H.R. 891/S. 274: All provisions of the Medication Therapy Management Benefits Act of 2011; H.R. 905 /S. 733: All provisions of the legislation to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare; H.R. 979 - All provisions of the FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act H.R. 4 /S.18 / S.72 - All provisions of the Small Business Paperwork Mandate Elimination Act H.R. 605 / S. 312 - All provisions of the Patients Freedom to Choose Act S. 27 - All provisions of the Preserve Access to Affordable Generics Act S. 31 - All provisions of the Prescription Drug and Health Improvement Act of 2011 S. 44 - All provisions of the Medicare Prescription Drug Price Negotiation Act of 2011 H.R. 999 / S. 560 - All provisions of the Medicare Prescription Drug Savings and Choice Act of 2011 H.R. 1839 - All provisions of the Community Pharmacy Fairness Act of 2011; H.R. 1946 - All provisions of the Preserving or Hometown Independent Pharmacies Act of 2011; H.R. 1971 / S. 1058 - All provisions of the Pharmacy Competition and Consumer Choice Act of 2011 Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, value-based insurance design, e-prescribing, PBM disclosure requirements, and medical loss ratio) Regulatory and proposed legislative changes to Medicare part D including EGWP waivers, MTM expansion, long term care short-term fills, recovery audit contractors Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs Regulatory Implementation of the HITECH Act FDA issues related to the Prescription Drug User Fee Act (PDUFA) (generic user fees, pedigree, REMs), implementation of approval pathway for generic biologic drugs 340b program H.R. 2245/S. 296 - All provisions of the Preserving Access to Life-Saving Medications Act of 2011

Client expense: $518,430 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Labor, Dept of (DOL), SENATE

HR 905/S 733 ASP legislation, health IT and meaningful use, radiation and reimbursement issues, SGR Medicare physician payments

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 905 / S. 733, to amend Part B of title XVIII of the Social Security Act. Meetings / education regarding physician and pharmacy reimbursement issues. Implementation of the Affordable Care Act.

Client expense: $300,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), SENATE

H.R. 905 and S. 733 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. ASP Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation.

Client expense: $220,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

H.R. 905 and S. 733 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. H.R. 1483, Drug Safety Enhancement Act of 2011, provisions related to pharmaceutical pedigree, wholesale transaction documentation, and electronic tracking. H.R. 3026, Safeguarding America's Pharmaceuticals Act, provisions related to pharmaceutical pedigree anti-counterfeiting. S. 1584, Drug Safety and Accountability Act of 2011, provisions related to pharmaceutical pedigree anti-counterfeiting. Preserving Access to Life-Saving Medications Act (H.R. 2245, S. 296), provisions related to drug shortages.

Client expense: $220,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

H.R. 905 / S. 733, to amend Part B of title XVIII of the Social Security Act. Meetings / education regarding physician and pharmacy reimbursement issues. Implementation of the Affordable Care Act.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), SENATE, Treasury, Dept of

Legislative proposals related to prompt pay discounts for drugs and biologicals under Medicare Part B, including S. 733 and H.R. 905; federal policy regarding proposed changes to Medicare drug reimbursement average sales price (ASP) formula; ASP generally (in the context of Deficit Reduction).

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

FY13 Labor HHS Appropriations legislation; issues related to FDA user fee reauthorization; H.R. 942; S. 1577; S. 3187; Pedigree and biologics issues; H.R. 905; ASP issues; H.R. 5651

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Implementation of the Patient Protection and Affordable Care Act; issues related to Medicare drug reimbursement; S. 733 and H.R. 905, provisions related to prompt pay discounts for drugs and biologicals under Medicare Part B; ASP Generally; H.R. 3630, A bill to extend the payroll tax holiday and for other purposes.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 905/733: A bill to amend Part B of Title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologics under Medicare. General issues related to the sustainable growth rate, physician payment reform and quality reporting.

Client expense: $45,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

- HR 905/ S 733, "To Amend Part B or Title XVIII of the Social Security Act to exclude customary prompt pay discounts from Manufacturers to Wholesalers from the average sales price for drugs & biologicals under Medicare", regarding all provisions. - HR 1041, "The Fairness in Medicare Bidding Act", regarding all provisions. - Issues related to Medicare reimbursement for Clinical Laboratory Services. - HR 1041, "Fairness in Medicare Bidding Act", regarding all provisions. - Medicare Part D Letter - HR 452, "Medicare Decisions Accountability Act of 2011", regarding all provisions. - S 668, "Health Care Bureaucrats Elimination Act", regarding all provisions. - Issues related to Physician-owned Companies that manufacture or distribute medical devices. - S 1468/ HR 2787, "Medicare Diabetes Self-Management Training Act of 2011", regarding all provisions. - PL 112-96, "Middle Class Tax Relief and Job Creation Act of 2012", provisions regarding Medicare clinical laboratory services. - Issues related to implantable medical devices. - HR 5998, "USPSTF Transparency and Accountability Act of 2012", regarding all provisions.

Client expense: $1,420,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)

H.R.905 - To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare. S.733 - A bill to amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare. S.89 - Withholding Tax Relief Act of 2011 S.164 - Withholding Tax Relief Act of 2011 H.R.1483 - Drug Safety Enhancement Act of 2011 H.R.3026 - Safeguarding America's Pharmaceuticals Act of 2011 S.1584 - Drug Safety and Accountability Act of 2011 H.R.2245 - Preserving Access to Life-Saving Medications Act of 2011 S.296 - Preserving Access to Life-Saving Medications Act H.R. 5651 - Food and Drug Administration Reform Act of 2012 S. 3187 - Food and Drug Administration Safety and Innovation Act

Client expense: Not reported · Firm income: $10,000

Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE

H.R.905 - To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare. S.733 - A bill to amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare. S.89 - Withholding Tax Relief Act of 2011 S.164 - Withholding Tax Relief Act of 2011 H.R.1483 - Drug Safety Enhancement Act of 2011 H.R.3026 - Safeguarding America's Pharmaceuticals Act of 2011 S.1584 - Drug Safety and Accountability Act of 2011 H.R.2245 - Preserving Access to Life-Saving Medications Act of 2011 S.296 - Preserving Access to Life-Saving Medications Act H.R. 5651 - Food and Drug Administration Reform Act of 2012 S. 3187 - Food and Drug Administration Safety and Innovation Act

Client expense: Not reported · Firm income: $10,000

Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE

**see addendum page Reimbursement for prescription drugs - Average Sales Price (H.R. 905/S. 733) PL 111-148 - The Patient Protection and Affordable Care Act, PL 111-152 - The Reconciliation Act of 2010, implementation, AMP, 340B, NADAC

Client expense: Not reported · Firm income: $60,000

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

H.R.905 and S.733, legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. H.R. 1483, H.R.3026 and S.1584, pharmaceutical pedigree anti-counterfeiting legislation. H.R.2245 and S.296, legislation pertaining to drug manufacturing shortages.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.905 and S.733, legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. ASP Generally (in the context of deficit reduction).

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

ASP reimbursement policy Pharmaceutical distribution reimbursement H.R.905/S.733-- Excluding customary prompt pay discounts from ASP Drug Shortages

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)

Client expense: $423,292 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), SENATE, White House Office

Average Sales Price (H.R. 905/S. 733); PPACA Implementation (PL 111-148); Centers for Medicare and Medicaid Services (AMP and NADAC)

Client expense: $222,819 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 905 & S. 733 Average Sales Price

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 905/S 733 ASP legislation; health IT and meaningful use; radiation and reimbursement issues; SGR Medicare physician payments

Client expense: Not reported · Firm income: $40,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 905/S.733, to amend Part B of title XVIII of the Social Security Act. Meetings/education regarding physician and pharmacy reimbursement issues. Implementation of the Affordable Care Act.

Client expense: $380,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

H.R. 905/ S. 733, to amend Part B of title XVIII of the Social Security Act. Meetings/education regarding physician and pharmacy reimbursement issues. Implementation of the Affordable Care Act.

Client expense: Not reported · Firm income: $110,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

ASP reimbursement policy Pharmaceutical distribution reimbursement H.R. 905/S.733-- Excluding customary prompt pay discounts from ASP Pharmaceutical pedigree anti-counterfeiting legislation-- H.R.1483, H.R.3026, S.1584 Drug Shortages Track and Trace legislation

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

FY13 Labor HHS Appropriations legislation; issues related to FDA user fee reauthorization; H.R. 942; S. 1577; S. 3187; Pedigree and biologics issues; H.R. 905; ASP issues; H.R. 5651

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Implementation of the Patient Protection and Affordable Care Act; issues related to Medicare drug reimbursement; S. 733 and H.R. 905, provisions related to prompt pay discounts for drugs and biologicals under Medicare Part B; ASP Generally; H.R. 3630, A bill to extend the payroll tax holiday and for other purposes.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE